Hazar, VolkanÖztürk, GülyüzYalçın, KorayUygun, VedatAksoylar, SerapKüpesiz, A.Bozkaya, İkbal OkKaragün, Barbaros ŞahinBozkurt, Ceyhunİleri, TaliaAtay, DidemKoçak, ÜlkerKarasu, Gülsün TezcanYeşilipek, AkifGökçe, MügeKansoy, SavasKintrup, Gulen TüysüzKarakukcu, MusaOkur, Fatma VisalErtem, MehmetKaya, ZühreGürsel, OrhanYaman, YöntemÖzbek, NamıkAntmen, BülentTüfekci, ÖzlemAlbayrak, CananAksoy, Başak AdakliSezgin, GülayAlbayrak, DavutEvim, Melike SezginZengin, EminePekpak, Esra2024-06-072024-06-072021-08-202666-6375https://doi.org/10.1016/j.jtct.2021.06.023https://www.sciencedirect.com/science/article/pii/S2666636721010265https://hdl.handle.net/11452/41858Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most frequent cause of post-transplantation mortality. Isolated extramedullary (EM) relapse (iEMR) after HSCT is relatively rare and not well characterized, particularly in pediatric patients. We retrospectively analyzed 1527 consecutive pediatric patients with acute leukemia after allo-HSCT to study the incidence, risk factors, and outcome of iEMR compared with systemic relapse. The 5 -year cumulative incidence of systemic relapse (either bone marrow [BM] only or BM combined with EMR) was 24.8%, and that of iEMR was 5.5%. The onset of relapse after allo-HSCT was significantly longer in EM sites than in BM sites (7.19 and 5.58 months, respectively; P =.013). Complete response (CR) 2 +/active disease at transplantation (hazard ratio [HR], 3.1; P <.001) and prior EM disease (HR, 2.3; P =.007) were independent risk factors for iEMR. Chronic graft-versus-host disease reduced the risk of systemic relapse (HR, 0.5; P=.043) but did not protect against iEMR. The prognosis of patients who developed iEMR remained poor but was slightly better than that of patients who developed systemic relapse (3 -year overall survival, 16.5% versus 15.3%; P =.089). Patients experiencing their first systemic relapse continued to have further systemic relapse, but only a minority progressed to iEMR, whereas those experiencing their iEMR at first relapse developed further systemic relapse and iEMR at approximately similar frequencies. A second iEMR was more common after a first iEMR than after a first systemic relapse (58.8% versus 13.0%; P =.001) and was associated with poor outcome. iEMR has a poor prognosis, particularly after a second relapse, and effective strategies are needed to improve outcomes. (C) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.eninfo:eu-repo/semantics/openAccessBone-marrow-transplantationAcute myelogenous leukemiaMinimal residual diseaseTotal-body irradiationAcute myeloid-leukemiaPrognosisAMLAcute leukemiaPost-transplantation relapseChildrenHematologyImmunologyTransplantationArticle000701826600014859.e1859.e10271010.1016/j.jtct.2021.06.0232666-6367